Physician profile
Sumitha Ganji
NPI 1215252853
$3,091.81
in general payments reported to CMS, 2019-2025
24 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $339 · 2021: $196 · 2022: $174 · 2023: $428 · 2024: $770 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $430.16 | 2019-2025 | Jynarque |
| Amgen INC. | $402.28 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Vifor Pharma, INC. | $358.59 | 2019-2023 | Veltassa |
| Mallinckrodt Hospital Products INC. | $303.27 | 2020-2025 | Acthar |
| Fresenius USA Marketing, INC. | $271.76 | 2019-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $267.67 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $172.22 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $141.32 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $125.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $121.33 | 2024-2025 | |
| Akebia Therapeutics INC | $98.78 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $55.09 | 2019-2023 | Benlysta |
| Travere Therapeutics, INC. | $53.68 | 2022-2024 | |
| Ardelyx, INC. | $47.70 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $47.06 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $31.29 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $31.26 | 2019-2023 | Ultomiris |
| Shire North American Group INC | $25.35 | 2019 | |
| Lilly USA, LLC | $20.70 | 2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $18.57 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.60 | 2025 | |
| Novo Nordisk INC | $17.46 | 2025 | Ozempic |
| Ultragenyx Pharmaceutical INC. | $16.54 | 2022 | |
| Aurinia Pharma U.S., INC. | $16.23 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumitha Ganji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.